KYMR KYMERA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, KYMERA THERAPEUTICS INC reported revenue of $65.0M (up 466.4% from a year earlier), net income of −$61.2M and diluted EPS of −$0.62; over the last four quarters revenue was $105M and net income $323M; for the fiscal year ended December 2025 revenue was $39.2M, down 16.7% on the year before.

KYMR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $39.2M, gross profit n/a, operating income −$349M, net income $311M (margin 794.0%), EPS −$3.69
• Fiscal year ended Dec 2024: revenue $47.1M, gross profit n/a, operating income −$262M, net income $224M (margin 475.6%), EPS −$2.98
• Fiscal year ended Dec 2023: revenue $78.6M, gross profit n/a, operating income −$166M, net income $147M (margin 187.0%), EPS −$2.52
• Fiscal year ended Dec 2022: revenue $46.8M, gross profit n/a, operating income −$161M, net income $155M (margin 330.6%), EPS −$2.87
• Fiscal year ended Dec 2021: revenue $72.8M, gross profit n/a, operating income −$101M, net income $100M (margin 137.6%), EPS −$2.09

KYMR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $65.0M (up 466.4% year over year), net income −$61.2M, EPS −$0.62
• Quarter ended Mar 31, 2026: revenue $34.4M (up 55.5% year over year), net income −$69.2M, EPS −$0.71
• Quarter ended Dec 31, 2025 (from the annual report): revenue $2.87M (down 61.2% year over year), net income $536M, EPS −$0.98
• Quarter ended Sep 30, 2025: revenue $2.76M (down 26.1% year over year), net income −$82.2M, EPS −$0.94
• Quarter ended Jun 30, 2025: revenue $11.5M (down 55.3% year over year), net income −$76.6M, EPS −$0.95
• Quarter ended Mar 31, 2025: revenue $22.1M (up 114.8% year over year), net income −$65.6M, EPS −$0.82
• Quarter ended Dec 31, 2024 (from the annual report): revenue $7.39M (down 84.6% year over year), net income $377M, EPS −$0.89
• Quarter ended Sep 30, 2024: revenue $3.74M (down 20.9% year over year), net income −$62.5M, EPS −$0.82
• Quarter ended Jun 30, 2024: revenue $25.7M (up 55.3% year over year), net income −$42.1M, EPS −$0.58
• Quarter ended Mar 31, 2024: revenue $10.3M (up 8.7% year over year), net income −$48.6M, EPS −$0.69
• Quarter ended Dec 31, 2023 (from the annual report): revenue $47.9M (up 196.7% year over year), net income $280M, EPS −$0.25
• Quarter ended Sep 30, 2023: revenue $4.73M (down 50.5% year over year), net income −$52.9M, EPS −$0.90
• Quarter ended Jun 30, 2023: revenue $16.5M (up 43.4% year over year), net income −$38.8M, EPS −$0.67
• Quarter ended Mar 31, 2023: revenue $9.47M (down 1.6% year over year), net income −$40.9M, EPS −$0.70
• Quarter ended Dec 31, 2022 (from the annual report): revenue $16.1M (up 5.7% year over year), net income $275M, EPS −$0.59
• Quarter ended Sep 30, 2022: revenue $9.55M (down 53.0% year over year), net income −$43.0M, EPS −$0.79
• Quarter ended Jun 30, 2022: revenue $11.5M (down 37.8% year over year), net income −$40.3M, EPS −$0.78
• Quarter ended Mar 31, 2022: revenue $9.62M (down 48.6% year over year), net income −$36.7M, EPS −$0.71
• Quarter ended Dec 31, 2021 (from the annual report): revenue $15.3M, net income $167M, EPS −$0.69
• Quarter ended Sep 30, 2021: revenue $20.3M, net income −$28.6M, EPS −$0.56

KYMR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$233M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$195M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$103M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$153M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$129M, share buybacks n/a

KYMR balance sheet

• Jun 30, 2026: cash $124M, total assets $1.65B, total liabilities $136M, shareholders' equity $1.51B
• Mar 31, 2026: cash $144M, total assets $1.67B, total liabilities $129M, shareholders' equity $1.54B
• Dec 31, 2025: cash $357M, total assets $1.74B, total liabilities $163M, shareholders' equity $1.58B
• Sep 30, 2025: cash $113M, total assets $1.10B, total liabilities $156M, shareholders' equity $946M
• Jun 30, 2025: cash $336M, total assets $1.13B, total liabilities $160M, shareholders' equity $971M
• Mar 31, 2025: cash $90.0M, total assets $918M, total liabilities $132M, shareholders' equity $786M
• Dec 31, 2024: cash $120M, total assets $978M, total liabilities $142M, shareholders' equity $836M
• Sep 30, 2024: cash $111M, total assets $1.03B, total liabilities $142M, shareholders' equity $893M

What is KYMR's revenue?

KYMERA THERAPEUTICS INC reported $105M of revenue over its last four quarters, through June 30, 2026.

Is KYMR profitable?

Yes. KYMERA THERAPEUTICS INC earned $323M over the last four quarters.

What is KYMR's EPS?

Diluted earnings per share over the last four quarters were −$3.25; −$0.62 in the latest quarter.

KYMR ownership and insider trades · All stocks